Concurrent treatment with OX40- and PD1-targeted cancer immunotherapies may be detrimental
Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.
Aug 28, 2017
0
0